Genmab | GEN - Gross Profit On Sales



Genmab reported DKK868M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
Almirall EUR 191.9M 185.49M Mar/2025
Amarin USD 25.13M 1.78M Mar/2025
Amgen USD 6.17B 624M Jun/2025
argenx SE USD 837.21M 127.34M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Bayer EUR 6.38B 1.74B Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Demant DKK 8.55B 33M Jun/2025
Exelixis USD 548.79M 12.52M Jun/2025
Fresenius Medical Care EUR 1.22B 31M Jun/2025
Galapagos EUR 61.25M 98.68M Mar/2025
Genmab DKK 868M 195M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
GN Store Nord DKK 2.31B 123M Jun/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 692M 64M Dec/2024
Insmed USD 78.08M 6.53M Jun/2025
Lonza CHF 1.04B 72M Dec/2024
Merck EUR 3.03B 118M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
UCB EUR 2.46B 520M Dec/2024